Newron
Ein Lebenszeichen 
- Safinamide data to be presented at World Congress on Parkinson´s disease and related disorders in Shanghai
Milan, Italy, December 13, 2011 – Newron Pharmaceuticals S.p.A. (“Newron”), a research and development company focused on novel CNS and pain therapies, announced today that new data on safinamide will be presented at the XIX World Congress on Parkinson’s Disease and Related Disorders (PDRD), December 11-14, 2011, in the Shanghai International Convention Center, Shanghai, China. Safinamide is currently being assessed in Phase III trials as add-on treatment to dopamine agonist or levodopa in early to late stage Parkinson’s disease (PD).
“Newron is very excited about the results to be presented at the World Congress and we expect that results of the ongoing phase III trials soon will further substantiate the emerging therapeutic profile of safinamide,” said Dr. Ravi Anand, Newron’s Chief Medical Officer.
The following abstracts have been accepted for presentation at the XIX World Congress:
First 2-year, placebo-controlled study in Parkinson's disease patients with motor fluctuations indicates safinamide may benefit patients with more severe dyskinesia
Presentation Date: Tuesday, December 13, 2011
Session Number: P005 Poster Session – Therapeutic Interventions
Poster Presentation Time: 8:00 AM – 6:00 PM (Present during breaks)
Two-year, placebo-controlled safety and tolerability data for safinamide as add-on to levodopa in patients with Parkinson's disease (PD)
Presentation Date: Tuesday, December 13, 2011
Session Number: P005 Poster Session – Therapeutic Interventions
Poster Presentation Time: 8:00 AM – 6:00 PM (Present during breaks)
Long-term efficacy of safinamide as add-on to levodopa in Parkinson's disease (PD) using an 'on' and 'on-off' treatment analysis
Presentation Date: Tuesday, December 13, 2011
Session Number: P005 Poster Session – Therapeutic Interventions
Poster Presentation Time: 8:00 AM – 6:00 PM (Present during breaks)
Safinamide as add-on to levodopa in Parkinson's disease with motor fluctuations may improve responder rates versus placebo during long-term treatment
Presentation Date: Tuesday, December 13, 2011
Session Number: P005 Poster Session – Therapeutic Interventions
Poster Presentation Time: 8:00 AM – 6:00 PM (Present during breaks)
About safinamide
Safinamide is an alpha-aminoamide that is currently being developed as an add-on therapy to dopamine agonists or levodopa in patients with early or late-stage Parkinson’s disease. It is believed to have both dopaminergic and non-dopaminergic activities, including selective and reversible inhibition of monoamine oxidase B (MAO-B), activity-dependent sodium channel antagonism and inhibition of glutamate release in vitro. Studies are ongoing to better understand safinamide’s actions in patients with Parkinson’s disease.
About Newron Pharmaceuticals
Newron Pharmaceuticals S.p.A. (http://www.newron.com) is a biopharmaceutical company focused on novel therapies for diseases of the Central Nervous System and pain. Phase III trials of safinamide are currently ongoing for the treatment of Parkinson’s disease (PD). Newron is currently evaluating the further clinical development of ralfinamide for pain and psychiatric diseases. Newron’s additional projects are at various stages of preclinical and clinical development, including HF0220 for neuroprotection, NW-3509 for the treatment of schizophrenia, as well as pruvanserin and sarizotan for treatment of CNS diseases. Newron is headquartered in Bresso, near Milan, Italy. The company is listed at SIX Swiss Exchange, trading symbol NWRN.
es kann weiter gegen Norden gehen